Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,752 across all filing types
Latest filing 2026-03-28 Proxy Solicitation & In…
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice convening a meeting of equity shareholders of Torrent Pharmaceuticals Limited pursuant to an order from the National Company Law Tribunal. The purpose of the meeting is to consider and approve a Scheme of Amalgamation between Torrent Pharmaceuticals Limited and J.B. Chemicals & Pharmaceuticals Limited. The document includes meeting details, voting instructions, and extensive annexures related to the merger scheme, financial statements, fairness opinions, legal proceedings, and other relevant information. This is clearly a notice for a shareholder meeting specifically convened to approve a merger/amalgamation scheme, which is a proxy solicitation and information statement type of filing. It is not the actual merger filing (which would be MA or TAR), nor is it a simple announcement or regulatory filing. The document is comprehensive and intended to solicit shareholder approval for the merger, fitting the Proxy Solicitation & Information Statement (PSI) category.
2026-03-28 English
Notice to shareholders for NCLT convened meeting
M&A Activity Classification · 95% confidence The document is a detailed notice convening a meeting of equity shareholders of Torrent Pharmaceuticals Limited pursuant to an order from the National Company Law Tribunal. The purpose of the meeting is to consider and approve a Scheme of Amalgamation with J.B. Chemicals & Pharmaceuticals Limited. The document includes meeting details, voting instructions, and extensive annexures such as explanatory statements, financial statements, board reports, valuation reports, fairness opinions, and legal proceedings related to the scheme. This is a formal notice and related materials for a shareholder meeting specifically convened to approve a merger/amalgamation scheme. It is not a full annual or interim financial report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement, but a notice to shareholders to convene and vote on a merger proposal. Therefore, the document best fits the category of M&A Activity (TAR) as it relates to merger proposals and takeover bids, including the scheme of amalgamation and related disclosures.
2026-03-27 English
Notice to Equity Shareholder for NCLT convened meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice convening a meeting of equity shareholders of Torrent Pharmaceuticals Limited pursuant to an order from the National Company Law Tribunal (NCLT) regarding a Scheme of Amalgamation with J.B. Chemicals & Pharmaceuticals Limited. It includes meeting details, voting instructions, and extensive annexures related to the merger scheme, financial statements, fairness opinions, legal proceedings, and other regulatory documents. The content is focused on informing shareholders about the meeting to approve the merger scheme and related resolutions, which is typical of a Proxy Solicitation & Information Statement (PSI). It is not a full annual or interim report, earnings release, or a simple announcement. The document is comprehensive and contains substantive information for shareholders to make an informed voting decision on the merger proposal. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2026-03-27 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice convening a meeting of equity shareholders pursuant to an order of the National Company Law Tribunal (NCLT) related to a Scheme of Amalgamation between two companies. It includes details about the meeting date, mode (video conferencing), e-voting procedures, and references to various annexures including financial statements, board reports, valuation reports, and legal proceedings. The primary purpose is to inform shareholders about the meeting to approve the Scheme of Amalgamation and to facilitate voting. This is not a full financial report, audit report, or earnings release, but a formal notice for a shareholder meeting related to a corporate restructuring event. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings, especially in the context of mergers or schemes requiring shareholder approval.
2026-03-27 English
Announcement under regulation 30 of SEBI (LODR) - Corrigendum
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to the stock exchanges (BSE and NSE) regarding an update on a legal order from the National Company Law Tribunal related to a proposed amalgamation (merger) of two companies. It references a corrigendum order and is an intimation under SEBI Listing Regulations. The content is an announcement of a regulatory/legal update related to a merger process, but it does not contain detailed merger documents or financial data. The document length is only 1378 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the merger process, not a full merger filing (MA) or merger proxy statement.
2026-03-25 English
General Updates
M&A Activity Classification · 95% confidence The document is a short letter addressed to the stock exchange's listing department, referencing a regulatory intimation under SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It informs about a corrigendum order issued by the National Company Law Tribunal related to a proposed amalgamation (merger) of two companies. The document is brief (1378 characters) and serves as an official notification of a regulatory event rather than a detailed merger filing or report. It does not contain detailed merger documents or financial data but is an announcement of a regulatory development related to M&A activity. According to the classification rules, such announcements about merger-related regulatory orders fall under M&A Activity (TAR).
2026-03-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.